See more : Kerry Group plc (KRZ.IR) Income Statement Analysis – Financial Results
Complete financial analysis of XOMA Corporation (XOMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of XOMA Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Taiga Motors Corporation (TAIG.TO) Income Statement Analysis – Financial Results
- UBE Corporation (UBEOY) Income Statement Analysis – Financial Results
- African Gold Acquisition Corpor (AGAC-WT) Income Statement Analysis – Financial Results
- Superhouse Limited (SUPERHOUSE.NS) Income Statement Analysis – Financial Results
- Decibel Cannabis Company Inc. (DB.V) Income Statement Analysis – Financial Results
XOMA Corporation (XOMA)
About XOMA Corporation
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.76M | 6.03M | 38.16M | 29.39M | 18.37M | 5.30M | 52.69M | 5.56M | 55.45M | 18.87M | 35.45M | 33.78M | 58.20M | 33.64M | 98.43M | 67.99M | 84.25M | 29.50M | 18.67M | 3.67M | 24.41M | 29.95M | 17.28M | 6.66M | 2.40M | 6.30M | 18.40M | 3.60M | 1.20M | 1.70M | 600.00K | 5.10M | 17.10M | 20.50M | 10.40M | 5.00M | 7.70M | 100.00K | 7.30M |
| Cost of Revenue | 897.00K | 97.00K | 171.00K | 170.00K | 1.25M | 1.68M | 7.88M | 1.40M | 20.70M | 29.47M | 27.36M | 143.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.37M | 0.00 | 0.00 | 0.00 | 1.87M | -1.20M | -1.60M | -2.00M | -2.10M | -2.90M | -3.30M | -2.60M | -800.00K | 6.50M | 5.60M | 24.20M | 14.50M | -1.40M | 41.40M | 8.50M |
| Gross Profit | 3.86M | 5.93M | 37.99M | 29.22M | 17.12M | 3.62M | 44.82M | 4.16M | 34.75M | -10.60M | 8.09M | 33.64M | 58.20M | 33.64M | 98.43M | 67.99M | 84.25M | 29.50M | 18.67M | -12.71M | 24.41M | 29.95M | 17.28M | 4.79M | 3.60M | 7.90M | 20.40M | 5.70M | 4.10M | 5.00M | 3.20M | 5.90M | 10.60M | 14.90M | -13.80M | -9.50M | 9.10M | -41.30M | -1.20M |
| Gross Profit Ratio | 81.15% | 98.39% | 99.55% | 99.42% | 93.18% | 68.26% | 85.05% | 74.84% | 62.67% | -56.19% | 22.82% | 99.58% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -346.74% | 100.00% | 100.00% | 100.00% | 71.93% | 150.00% | 125.40% | 110.87% | 158.33% | 341.67% | 294.12% | 533.33% | 115.69% | 61.99% | 72.68% | -132.69% | -190.00% | 118.18% | -41,300.00% | -16.44% |
| Research & Development | 143.00K | 153.00K | 171.00K | 170.00K | 1.25M | 1.68M | 7.88M | 44.23M | 70.85M | 80.75M | 74.85M | 68.32M | 68.14M | 77.41M | 58.13M | 82.58M | 66.22M | 52.09M | 39.90M | 49.78M | 57.46M | 42.62M | 35.93M | 30.01M | 41.50M | 43.80M | 29.90M | 26.40M | 22.10M | 27.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 25.61M | 23.19M | 20.46M | 16.80M | 21.00M | 18.56M | 24.34M | 18.32M | 20.62M | 19.87M | 18.48M | 16.87M | 24.01M | 23.25M | 23.74M | 24.15M | 20.58M | 18.09M | 14.80M | 31.98M | 24.49M | 19.41M | 8.68M | 6.07M | 6.10M | 5.40M | 5.60M | 5.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.61M | 23.19M | 20.46M | 16.80M | 21.00M | 18.56M | 24.34M | 18.32M | 20.62M | 19.87M | 18.48M | 16.87M | 24.01M | 23.25M | 23.74M | 24.15M | 20.58M | 18.09M | 14.80M | 31.98M | 24.49M | 19.41M | 8.68M | 6.07M | 6.10M | 5.40M | 5.60M | 5.50M | 5.40M | 8.70M | 35.10M | 41.80M | 49.90M | 37.80M | 7.50M | 3.90M | 13.00M | 4.00M | 3.00M |
| Other Expenses | 20.71M | 97.00K | -879.00K | 1.23M | 3.82M | 4.34M | 1.12M | 1.51M | 44.00K | -31.00K | -197.00K | -956.00K | 0.00 | 82.00K | 3.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.87M | 1.20M | 1.60M | 2.00M | 2.10M | 2.90M | 3.30M | 2.80M | 3.00M | 2.00M | 1.80M | 1.40M | 800.00K | 1.40M | 2.00M | 1.40M |
| Operating Expenses | 46.46M | 23.44M | 20.63M | 16.97M | 22.26M | 20.25M | 32.21M | 62.56M | 91.47M | 100.61M | 93.33M | 85.19M | 92.15M | 100.66M | 81.87M | 106.72M | 86.80M | 70.18M | 54.69M | 81.76M | 81.95M | 62.03M | 44.61M | 34.21M | 48.80M | 50.80M | 37.50M | 34.00M | 30.40M | 39.30M | 37.90M | 44.80M | 51.90M | 39.60M | 8.90M | 4.70M | 14.40M | 6.00M | 4.40M |
| Cost & Expenses | 46.61M | 23.44M | 20.63M | 16.97M | 22.26M | 20.25M | 32.21M | 62.56M | 91.47M | 100.61M | 93.33M | 85.33M | 92.15M | 100.66M | 81.87M | 106.72M | 86.80M | 70.18M | 54.69M | 81.76M | 81.95M | 62.03M | 44.61M | 36.08M | 47.60M | 49.20M | 35.50M | 31.90M | 27.50M | 36.00M | 35.30M | 44.00M | 58.40M | 45.20M | 33.10M | 19.20M | 13.00M | 47.40M | 12.90M |
| Interest Income | 0.00 | 0.00 | 35.00K | 159.00K | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 49.00K | 859.00K | 0.00 | 1.68M | 1.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 569.00K | 0.00 | 461.00K | 1.84M | 1.92M | 922.00K | 1.24M | 3.95M | 4.18M | 4.28M | 4.63M | 4.34M | 2.46M | 385.00K | 4.89M | 7.00M | 0.00 | 12.93M | 4.25M | 0.00 | 1.88M | 0.00 | 0.00 | 2.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 900.00K | 274.00K | 167.00K | 172.00K | 1.92M | 30.00K | 304.00K | 769.00K | 1.53M | 1.86M | 2.58M | 4.12M | 5.36M | 5.72M | 6.83M | 8.12M | 6.73M | 6.17M | 5.77M | 4.55M | 3.99M | 2.12M | 1.25M | -1.87M | 1.20M | 1.60M | 2.00M | 2.10M | 2.90M | 3.30M | 2.80M | 3.00M | 2.00M | 1.80M | 1.40M | 800.00K | 1.40M | 2.00M | 1.40M |
| EBITDA | -39.36M | -16.85M | 16.52M | 13.81M | 1.85M | -12.49M | 20.78M | -48.82M | -15.31M | -32.14M | -116.87M | -62.63M | -24.91M | -62.62M | 18.00M | -31.91M | 4.19M | -34.51M | -36.03M | -73.16M | -53.55M | -29.96M | -26.08M | -31.29M | -44.00M | -41.30M | -15.20M | -26.20M | -23.40M | -31.00M | -31.90M | -35.90M | -39.30M | -22.90M | -21.30M | -13.40M | -3.90M | -45.30M | -4.20M |
| EBITDA Ratio | -827.28% | -282.31% | 43.63% | 46.42% | -0.34% | -200.19% | 40.98% | -997.16% | -62.15% | -423.76% | -163.81% | -143.35% | -49.14% | -182.17% | 23.82% | -44.89% | 5.05% | -117.34% | -382.61% | -2,017.08% | -222.46% | -102.94% | -162.25% | -510.12% | -1,883.33% | -552.38% | -89.67% | -702.78% | -2,266.67% | -1,805.88% | -5,916.67% | -549.02% | -281.29% | -145.37% | -290.38% | -344.00% | -57.14% | -47,200.00% | -68.49% |
| Operating Income | -41.85M | -17.41M | 17.53M | 12.42M | -3.89M | -16.86M | 17.03M | -61.56M | -39.72M | -81.83M | -58.21M | -56.62M | -33.96M | -67.10M | 12.96M | -38.73M | -2.54M | -40.68M | -36.03M | -78.10M | -57.54M | -32.08M | -27.33M | -29.42M | -45.20M | -42.90M | -17.10M | -28.30M | -26.30M | -34.30M | -34.70M | -38.90M | -41.30M | -24.70M | -22.70M | -14.20M | -5.30M | -47.30M | -5.60M |
| Operating Income Ratio | -879.53% | -288.93% | 45.94% | 42.25% | -21.15% | -318.12% | 32.32% | -1,106.36% | -71.64% | -433.75% | -164.18% | -167.62% | -58.35% | -199.47% | 13.17% | -56.97% | -3.02% | -137.92% | -192.97% | -2,130.86% | -235.70% | -107.11% | -158.17% | -441.75% | -1,883.33% | -680.95% | -92.93% | -786.11% | -2,191.67% | -2,017.65% | -5,783.33% | -762.75% | -241.52% | -120.49% | -218.27% | -284.00% | -68.83% | -47,300.00% | -76.71% |
| Total Other Income/Expenses | 1.02M | 295.00K | -1.64M | -619.00K | 1.90M | 3.42M | -773.00K | 8.03M | 19.12M | 43.53M | -65.87M | -14.52M | 1.23M | -1.63M | -6.68M | -6.89M | -9.78M | -11.16M | 38.81M | -846.00K | -1.12M | 871.00K | 1.96M | 2.68M | 1.20M | -6.50M | 1.50M | -900.00K | 3.80M | -300.00K | 3.60M | -7.90M | 8.80M | 6.90M | 8.90M | 3.80M | 500.00K | 1.90M | 800.00K |
| Income Before Tax | -40.83M | -17.12M | 15.89M | 11.80M | -1.98M | -13.44M | 16.26M | -53.53M | -20.61M | -38.30M | -124.07M | -71.14M | -32.73M | -68.73M | 6.28M | -45.63M | -12.33M | -51.84M | 2.78M | -78.94M | -58.65M | -31.21M | -25.37M | -26.73M | -44.00M | -49.40M | -15.70M | -29.20M | -22.50M | -34.60M | -31.10M | -46.80M | -32.50M | -17.80M | -13.80M | -10.40M | -4.80M | -45.40M | -4.80M |
| Income Before Tax Ratio | -858.15% | -284.04% | 41.64% | 40.15% | -10.79% | -253.65% | 30.86% | -962.08% | -37.16% | -203.02% | -349.98% | -210.58% | -56.24% | -204.30% | 6.38% | -67.11% | -14.63% | -175.74% | 14.90% | -2,153.94% | -240.26% | -104.20% | -146.84% | -401.44% | -1,833.33% | -784.13% | -85.33% | -811.11% | -1,875.00% | -2,035.29% | -5,183.33% | -917.65% | -190.06% | -86.83% | -132.69% | -208.00% | -62.34% | -45,400.00% | -65.75% |
| Income Tax Expense | 0.00 | -15.00K | 91.00K | -1.50M | 5.72M | -98.00K | 1.66M | 4.69M | 4.23M | 4.25M | -14.00K | -74.00K | 15.00K | 27.00K | 5.73M | -383.00K | 9.78M | 11.16M | 3.00K | 846.00K | 1.12M | 1.17M | 709.00K | -4.00K | 600.00K | 4.30M | -1.30M | 800.00K | -3.80M | 300.00K | -3.40M | 8.20M | -7.00M | -1.00M | -3.80M | -2.20M | -500.00K | -600.00K | -800.00K |
| Net Income | -40.83M | -17.10M | 15.80M | 13.30M | -7.70M | -13.34M | 14.60M | -53.53M | -20.61M | -38.30M | -124.06M | -71.07M | -32.74M | -68.76M | 550.00K | -45.25M | -12.33M | -51.84M | 2.78M | -78.94M | -58.65M | -33.25M | -28.04M | -29.41M | -45.80M | -47.20M | -15.80M | -29.10M | -22.50M | -34.60M | -31.30M | -47.10M | -34.30M | -23.70M | -18.90M | -12.00M | -4.80M | -46.70M | -4.80M |
| Net Income Ratio | -858.15% | -283.79% | 41.40% | 45.25% | -41.91% | -251.80% | 27.70% | -962.08% | -37.16% | -203.02% | -349.94% | -210.36% | -56.26% | -204.38% | 0.56% | -66.55% | -14.63% | -175.74% | 14.89% | -2,153.94% | -240.26% | -111.01% | -162.28% | -441.69% | -1,908.33% | -749.21% | -85.87% | -808.33% | -1,875.00% | -2,035.29% | -5,216.67% | -923.53% | -200.58% | -115.61% | -181.73% | -240.00% | -62.34% | -46,700.00% | -65.75% |
| EPS | -4.04 | -1.50 | 1.40 | 1.25 | -0.88 | -1.59 | 0.75 | -8.89 | -3.50 | -7.13 | -28.60 | -22.00 | -20.73 | -73.88 | 1.00 | -102.11 | -28.90 | -162.07 | 9.00 | -279.09 | -234.39 | -141.77 | -123.42 | -136.34 | -260.70 | -330.11 | -119.86 | -268.67 | -285.16 | -474.00 | -438.00 | -660.00 | -531.00 | -504.00 | -429.00 | -336.00 | -165.06 | -1.91K | -171.00 |
| EPS Diluted | -4.04 | -1.50 | 1.30 | 1.16 | -0.88 | -1.59 | 0.73 | -8.89 | -3.50 | -6.64 | -28.54 | -21.99 | -20.73 | -73.88 | 0.97 | -102.11 | -28.90 | -162.07 | 9.00 | -279.09 | -234.39 | -141.77 | -123.42 | -136.34 | -260.70 | -330.11 | -119.86 | -268.67 | -285.16 | -474.00 | -438.00 | -660.00 | -531.00 | -504.00 | -429.00 | -336.00 | -165.06 | -1.91K | -171.00 |
| Weighted Avg Shares Out | 11.47M | 11.41M | 11.29M | 10.67M | 8.76M | 8.37M | 7.62M | 6.02M | 5.89M | 5.37M | 4.34M | 3.23M | 1.58M | 930.65K | 549.65K | 443.10K | 426.49K | 319.87K | 287.14K | 282.86K | 250.23K | 234.52K | 227.20K | 215.73K | 175.68K | 142.98K | 131.82K | 108.31K | 78.90K | 73.00K | 71.46K | 71.36K | 64.60K | 47.02K | 44.06K | 35.71K | 29.08K | 24.48K | 28.07K |
| Weighted Avg Shares Out (Dil) | 11.47M | 11.41M | 12.19M | 11.50M | 8.76M | 8.37M | 7.98M | 6.02M | 5.89M | 5.77M | 4.35M | 3.23M | 1.58M | 930.65K | 565.65K | 443.10K | 426.49K | 319.87K | 300.21K | 282.86K | 250.23K | 234.52K | 227.20K | 215.73K | 175.68K | 142.98K | 131.82K | 108.31K | 78.90K | 73.00K | 71.46K | 71.36K | 64.60K | 47.02K | 44.06K | 35.71K | 29.08K | 24.48K | 28.07K |
XOMA Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock:
XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference
EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference held on September 13-15, 2021. The presentation will...
I Put Half Of My Retirement Savings Into These Investments
Half of my retirement savings is invested in two sectors.
XOMA Announces Heather L. Franklin Joins its Board of Directors
EMERYVILLE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined the Company's Board of Directors. Ms. Franklin has significant experience in corporate...
XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events
Added six assets to its portfolio of potential milestone and royalty assets in 2021
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros's license agreement with Checkmate Pharmaceuticals
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Ad hoc announcement pursuant to Article 53 of the SIX listing rules
XOMA Acquires Royalty and Milestone Interest in Checkmate's Vidutolimod (CMP-001) from Kuros Biosciences
EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals' vidutolimod (CMP-001), an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle,...
Stem, Tesla, Textron, Two Harbors and More Tuesday Afternoon Analyst Calls
Stocks were mostly higher in midday Tuesday trading, after both the S&P 500 and the Nasdaq closed at record highs on Monday.
XOMA Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock:
XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting
EMERYVILLE, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) recently learned its licensees are presenting at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 4-8, 2021, in a virtual setting.
Source: https://incomestatements.info
Category: Stock Reports
What were XOMA’s total revenues in 2023?
XOMA recorded total revenues of $1.8 million and $4.8 million for the fourth quarter and full year of 2023, respectively.